Abstract
The authors conducted a retrospective cohort study of female patients diagnosed with breast cancer (BRCA), evaluating the risk of new-onset depression associated with tamoxifen treatment among those with estrogen receptor-positive (ER+) tumors, versus estrogen receptor-negative (ER-) tumors, who were not receiving tamoxifen. A total cohort of 2,943 patients was identified. The hazard-ratio for new-onset depression in the tamoxifen group was nonsignificant. A post-hoc analysis revealed that chemotherapy and ER+ status were significantly and independently associated with an increased risk for developing depression.
MeSH terms
-
Antineoplastic Agents, Hormonal / adverse effects*
-
Antineoplastic Agents, Hormonal / therapeutic use
-
Breast Neoplasms / drug therapy*
-
Breast Neoplasms / metabolism
-
Breast Neoplasms / psychology*
-
Cohort Studies
-
Depressive Disorder / chemically induced*
-
Depressive Disorder / diagnosis
-
Depressive Disorder / psychology
-
Female
-
Humans
-
Middle Aged
-
Receptors, Estrogen / antagonists & inhibitors
-
Receptors, Estrogen / biosynthesis
-
Retrospective Studies
-
Risk Assessment / methods
-
Risk Factors
-
Tamoxifen / adverse effects*
-
Tamoxifen / therapeutic use
-
Time Factors
Substances
-
Antineoplastic Agents, Hormonal
-
Receptors, Estrogen
-
Tamoxifen